---
title: "CytomX Therapeutics to Launch Phase 1 Varseta-M Combination Study in Colorectal Cancer"
description: "CytomX Therapeutics Inc. is set to launch a Phase 1 combination study of varsetatug masetecan with bevacizumab in colorectal cancer in Q1 2026, with initial data expected in H1 2027. The company will "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/271935971.md"
published_at: "2026-01-08T13:00:25.000Z"
---

# CytomX Therapeutics to Launch Phase 1 Varseta-M Combination Study in Colorectal Cancer

> CytomX Therapeutics Inc. is set to launch a Phase 1 combination study of varsetatug masetecan with bevacizumab in colorectal cancer in Q1 2026, with initial data expected in H1 2027. The company will also present Phase 1 expansion data for CX-2051 in Q1 2026 and anticipates initial Phase 1 combination data for CX-801 with KEYTRUDA® in melanoma by the end of 2026. Updates will be shared at the 44th Annual JP Morgan Healthcare Conference on January 14, 2026.

CytomX Therapeutics Inc. has announced several upcoming milestones in its clinical development programs for 2026. The company plans to present Phase 1 colorectal cancer expansion data for CX-2051 (varsetatug masetecan) in the first quarter of 2026. Additionally, a Phase 1 combination study of varsetatug masetecan with bevacizumab in colorectal cancer is set to begin in the first quarter of 2026, with initial data expected in the first half of 2027. For CX-801, a masked interferon-alpha-2b, initial Phase 1 combination data with KEYTRUDA® (pembrolizumab) in melanoma is anticipated by the end of 2026. Earlier, CX-801 monotherapy biomarker data in advanced melanoma patients were presented at the 2025 Society of Immunotherapy of Cancer Annual Meeting. Further updates and presentations are scheduled, including the 44th Annual JP Morgan Healthcare Conference on January 14, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9622008) on January 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [CTMX.US - Cytomx Therap](https://longbridge.com/en/quote/CTMX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| OpenClaw 時代：Cloudflare 股票會是 2026 年人工智能領域的最大贏家嗎？ | 開放爪時代：Cloudflare 股票會是 2026 年最大的 AI 勝利者嗎？ | [Link](https://longbridge.com/en/news/276123602.md) |
| MoneyShow 2026 年精選股票：Perpetua Resources Corp. (PPTA) | MoneyShow 2026 年最佳推薦：Perpetua Resources Corp. (PPTA) | [Link](https://longbridge.com/en/news/275924909.md) |
| 盛禧奧修改了信貸協議，將利息寬限期延長至2026年3月19日 | 盛禧奧已修訂其信貸協議，將 2026 年 2 月 1 日至 2026 年 2 月 29 日到期的某些利息支付的寬限期延長至 2026 年 3 月 19 日。此延長與公司第二留置權票據的寬限期一致，並且是與金融利益相關者進行持續討論的一部分。 | [Link](https://longbridge.com/en/news/276118253.md) |
| 美國銀行稱，截至 2026 年 1 月底，信用卡拖欠率為 0.99% | 美國銀行公司：美國銀行公司的信用卡逾期率在 2026 年 1 月底為 0.99% - SEC 文件；美國銀行公司的信用卡壞賬率在 2026 年 1 月為 2.23% | [Link](https://longbridge.com/en/news/276144250.md) |
| Invesco Mortgage Capital Inc. 宣佈 2026 年 2 月的股息及2026年1月31日的財務更新 \| IVR 股票新聞 | Invesco Mortgage Capital Inc. 宣佈將於 2026 年 2 月支付每股現金股息 0.12 美元，支付日期為 2026 年 3 月 13 日。截至 2026 年 1 月 31 日，該公司報告的總投資組合為 71 億 | [Link](https://longbridge.com/en/news/275945261.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.